Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or...
Reexamination Certificate
2003-12-09
2008-09-02
Mosher, Mary E (Department: 1648)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
C435S236000
Reexamination Certificate
active
07419816
ABSTRACT:
A mutant virus contains a mutation at a phosphorylation site in one or more viral proteins, which attenuates the virus, and an improved vaccine composition. The invention also relates to methods of inducing an immune response, and protecting mammals from infection by rabies virus. Also included are methods of producing the mutant virus and mutant viral proteins, including producing the mutant virus in a host cell which produces or-overproduces a wild-type counterpart of the mutant viral protein, which complements the other viral proteins such that production of the mutant viral particle is optimized. The invention also includes those host cells, vaccine compositions including the viral proteins,-alone or in combination with-intact virus, and methods of inducing an immune response or protecting a mammal from infection. Also included are vectors suitable for delivering a gene to a cell of a human or animal, and methods of delivery thereof.
REFERENCES:
patent: 4342566 (1982-08-01), Theofilopoulos et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5853735 (1998-12-01), Benejean et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6706523 (2004-03-01), Fu
patent: 6719881 (2004-04-01), Hunter et al.
patent: 0583998 (1994-02-01), None
patent: WO 00/32755 (2000-06-01), None
patent: WO 00/32755 (2000-06-01), None
Clark et al., “Temperature-Sensitive Mutants of Rabies Virus in Mice: a Mutant (ts 2) Revertant Mixture Selectively Pathogenic by the Peripheral Route of Inoculation,” Infection and Immunity, vol. 13, No. 5, 1418-1425 (1976).
Wu et al (Journal of Virology 76:4153, 2002).
Morimoto et al (Journal of Virology 73: 510-518, 1999).
Chenik et al (Journal of General Virology 75:2889-2896, 1994).
Drings A. et al, “Is there an advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine?”,Vaccine,Mar. 1999, pp. 1549-1557, vol. 17, Nos. 11-12.
Supplementary Partial European Search Report.
Anzai J. et al., “Identification of a Phosphatase-Sensitive Epitope of Rabies Virus Nucleoprotein which is Recognized by a Monoclonal Antibody 5-2-26,” Microbiology and Immunology, 1997, pp. 229-240, vol. 41, No. 3, Tokyo, Japan.
Fu Z. F. et al., “Immunoprotection by Rabies Virus Nucleoprotein,” Current Topics in Microbiology and Immunology, 1994, pp. 161-172, Springer, Berlin, Germany.
Mebatsion T. et al., “Highly Stable Expression of a Foreign Gene from Rabies Virus Vectors,” Proceedings of the Nat'l. Acad. Of Sci. of USA, Jul. 1996, pp. 7310-7314, vol. 93, Nat'l. Acad. Of Sci., Washington, DC, U.S.
Morimoto, Kinjiro et al., “Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures,” Jnl. of Virology, Jan. 1999, pp. 510-518, vol. 73, No. 1, Amer. Soc. For Microbiology, U.S.
Morimoto, K. et al., “Genetic engineering of live rabies vaccines,” Vaccine, May 14, 2001, pp. 3543-3551, vol. 19, No. 25-26, Butterworth Scientific, Guildford, GB.
Tartaglia J. et al., “NYVAC: A Highly Attenuated Strain of Vaccinia Virus,” Virology, May 1, 1992, pp. 217-232, vol. 188, No. 1, Academic Press, Orlando, FL.
Supplementary European Search Report.
M.C. Anderson et al., “The role of specific IgE and beta-propiolactone in reactions resulting from booster doses of human diploid cell rabies vaccine”, J. Allergy Clin. Immunol., Dec. 1987, pp. 861-868, vol. 80, Food and Drug Administration, Bethesda, MD.
Anonymous. Compendium of Animal Rabies Prevention and Control, 2000, National Association of State Public Health Veterinarians, Inc., MMWR, pp. 21-30, vol. 49, No. RR-8.
Anonymous. Rabies Vaccine Failures [editorial], Lancet, Apr. 23, 1988, p. 917, vol. 1, The Lancet Publishing Group, London, UK.
G.M. Baer, “Oral Rabies Vaccination: An Overview”, Rev. Infect. Dis., Nov.-Dec. 1988, pp. S644-S647, vol. 10, Suppl. 4, Centers for Disease Control, Lawrencevile, Georgia.
L.A. Ball et al., “Phenotypic Consequences of Rearranging the P, M, and G Genes of Vesicular Stomatitis Virus”, J. Virol., Jun. 1999, pp. 4705-4712, vol. 73, No. 6, American Society for Microbiology, Washington, DC.
A.K. Banerjee et al., “Structure and Function of the RNA Polymerase of Vesicular Stomatitis Virus”, Advances in Virus Research, 1990, pp. 99-124, vol. 38, Academic Press.
J. Barr et al., “Sequence of the major nucleocapsid protein gene of pneumonia virus of mice: Sequence comparisons suggest structural homology between nucleocapsid proteins of pneumoviruses, paramyxoviruses, rhabdoviruses and filoviruses”, J. Gen. Virol., 1991, pp. 677-685, vol. 72, Society of General Microbiology, Great Britain.
R. Barth et al., “A new inactivated tissue culture rabies vaccine for use in man. Evaluation of PCEC-vaccine by laboratory tests”, J. Biol. Stand., 1984, pp. 29-64, vol. 12, The International Association of Biological Standardization, Academic Press.
J. Blancou et al., “Oral vaccination of the fox against rabies using a live recombinant vaccinia virus”, Nature, Jul. 1986, pp. 373-375, vol. 322, Macmillan Publishers Ltd., Hampshire, England.
P. Boudinot et al., “Viral haemorrhagic septicaemia virus inducesvig-2, a new intereron-responsive gene in rainbow trout”, Fish & Shellfish Immunol., 2001, pp. 383-397, vol. 11, Academic Press.
D.J. Briggs et al., “Safety and immunogenicity of Lyssavac Berna human diploid cell rabies vaccine in healthy adults”, Vaccine, 1996, pp. 1361-1365, vol. 14, No. 14, Elsevier Science Ltd., Great Britain.
B. Brochier et al., “Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine”, Nature, Dec. 1991, pp. 520-522, vol. 354, Macmillan Publishers Ltd., Hampshire, England.
B. Brochier et al., “Use of recombinant vaccinia-rabies virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species”, J. Wildl. Dis., 1989, pp. 540-547, vol. 25, Wildlife Disease Association, Lawrence, Kansas.
U.J. Buchholz et al., “Generation of Bovine Respiratory Syncytial Virus (BRSV) From cDNA: BRSV NS2 Is Not Essential For Virus Replication In Tissue Culture, And The Human RSV Leader Region Acts as a Functional BRSV Genome Promoter”, J. Virol., Jan. 1999, pp. 251-259, vol. 73, No. 1, American Society for Microbiology, Washington, DC.
K.M. Charlton et al., “Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine”, Arch. Virol., 1992, pp. 169-179, vol. 123, Springer-Verlag, Austria.
K.A. Clark et al., “Post-exposure rabies prophylaxis and pre-exposure rabies vaccination failure in domestic animals”, J. Am. Vet. Med. Assoc., Jun. 1, 1996, pp. 1827-1830, vol. 208, No. 11, American Veterinary Medical Association, Schaumburg, Illinois.
K.-K. Conzelmann et al., “Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins”, J. Virol., Feb. 1994, pp. 713-719, vol. 68, No. 2, American Society for Microbiology, Washington, DC.
K.-K. Conzelmann et al., “Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19”, J. Virol., 1990, pp. 485-499, vol. 175, Academic Press, Inc., Duluth, MN.
P. Coulon et al., “Invasion of the peripheral nervous systems of adult mice by the CVS strain of rabies virus and its avirulent derivative AvO1”, J. Virol., Aug. 1989, pp. 3550-3554, vol. 63, No. 8, American Society for Microbiology, Washington, DC.
J.H. Cox et al., “Rabies virus glycoprotein. II. Biological and serological characterization”, Infect Immun., Jun. 1977, pp. 754-759, vol. 16, American Society for Microbiology, Washington, DC.
B. Dietzschold et al., “Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus”, Proc. Natl
Bingham & McCutchen LLP
Mosher Mary E
University of Georgia Research Foundation Inc.
LandOfFree
Attenuated rabies virus with nucleoprotein mutation at the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuated rabies virus with nucleoprotein mutation at the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated rabies virus with nucleoprotein mutation at the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3992410